Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial
Dongsheng Wang(University of Science and Technology of China), Xiaoling Xu(Fujian Agriculture and Forestry University), Haiming Wei(University of Science and Technology of China), Tianjun Yang(University of Science and Technology of China), Daqing Xia(University of Science and Technology of China), Xiaowen Hu(Lanzhou University), Aijun Pan(University of Science and Technology of China), Zhen Peng(Cotton Research Institute), Wei Shi(Anhui Medical University), Yonggang Zhou(University of Science and Technology of China), Wei Li(Sun Yat-sen University), Min Zhang(Henan University of Science and Technology), Xiaojing Wang(Zhengzhou University), Yan Ma(Harbin Medical University), Yubei Sun(University of Science and Technology of China), Jun Chen(Bengbu Medical College), Dongliang Yang, Min Li(Nanjing Medical University), Yun Yang(Army Medical University), Xiaoyu Zhu(Jiangsu Hengrui Medicine (China)), Xin Yao(Tianjin Medical University Cancer Institute and Hospital), Xiaodong Mei(University of Chinese Academy of Sciences), Mingfeng Han(Chinese Academy of Medical Sciences & Peking Union Medical College), Liangye Sun(Anhui Medical University), Lin Dong(Capital Medical University), Binqing Fu(University of Science and Technology of China), Fei Xu(University of Science and Technology of China), Jumei Wang(University of Science and Technology of China)
Cited by 80
Related Papers
Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes
|Science|2011|6.6k
Archaea and Fungi of the Human Gut Microbiome: Correlations with Diet and Bacterial Residents
|PLoS ONE|2013|809
Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China
|JAMA Internal Medicine|2020|240